Related Experiment Videos
Integrating epithelial cancer, aging stroma and cellular senescence
1Lawrence Berkeley National Laboratory, Life Sciences Division, Mailstop 84-171, 1 Cyclotron Road, Berkeley, CA 94720, USA.
Advances in Gerontology = Uspekhi Gerontologii
|June 25, 2003
Summary
Cancer incidence increases with age due to accumulating mutations and a pro-tumorigenic tissue environment. Cellular senescence, particularly in stromal fibroblasts, contributes to this permissive environment, promoting age-related cancer progression.
Area of Science:
- Oncology
- Cell Biology
- Aging Research
Background:
- Cancer incidence rises exponentially with age.
- Cancer development requires oncogenic mutations and a permissive tissue environment.
- Age-related changes in the tissue microenvironment are increasingly recognized as critical factors in cancer progression.
Purpose of the Study:
- To explore the role of cellular senescence in creating a pro-oncogenic tissue environment.
- To investigate how age-related cellular senescence synergizes with oncogenic mutations.
- To understand the contribution of senescent cells to age-related cancer development.
Main Methods:
- Review of existing literature on cancer, aging, and cellular senescence.
- Analysis of the mechanisms by which senescent cells influence tissue microenvironment.
- Synthesis of evidence linking cellular senescence to age-related cancer progression.
Main Results:
- Cellular senescence, a state of irreversible cell cycle arrest, accumulates with age.
- Senescent cells, especially stromal fibroblasts, secrete factors that alter tissue architecture and promote proliferation.
- These senescence-associated secretory phenotypes can create a permissive environment for oncogenic mutations.
Conclusions:
- Cellular senescence is a key factor in the age-related increase in cancer incidence.
- Senescent cells contribute to a pro-tumorigenic tissue milieu, synergizing with mutations.
- Cellular senescence may represent a form of antagonistic pleiotropy in aging and cancer.